Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation

Abstract

Sorafenib can be well tolerated and safe in patients with recurrent HCC following LT and may be associated with a modest survival benefit. To our knowledge, this is the largest single-center retrospective analysis of patients prescribed sorafenib for recurrent HCC after LT.